PL EN


Preferences help
enabled [disable] Abstract
Number of results
2011 | 7 | 4 | 319-325
Article title

Biomarkery uszkodzenia miąższu nerek

Content
Title variants
EN
Biomarkers of kidney injury
Languages of publication
EN PL
Abstracts
EN
Acute kidney injury (AKI) is a syndrome defined by acute increase of serum creatinine or decrease in glomerular filtration rate (GFR). AKI is common in patients undergoing cardiac surgery, imaging modalities and endovascular procedures with using iodinated contrast, those who suffer from sepsis and other critically ill patients. Serum creatinine, the current main diagnostic test for AKI, rises late in AKI pathophysiology and is not precise marker of acute changes in glomerular filtration rate. The serum creatinine measurements are confounded by a large number of variables, including age, gender, race, muscle mass, muscle metabolism, hydration status and medications. New studies presented laboratory markers of AKI detected in serum and urine. These include cystatin C, NGAL, KIM-1, L- FABP, IL-18 and others. These new biomarkers offer promise for early AKI diagnosis and for the depiction of severity of renal injury occurring with AKI. They can reflect the progression of AKI to chronic kidney disease (CKD). The aim of this article is to review specific biomarkers for early detection of AKI and progression to CKD.
PL
Ostre uszkodzenie nerek (acute kidney injury, AKI) jest rozpoznawane w oparciu o stężenie kreatyniny w surowicy i upośledzenie filtracji kłębuszkowej (glomerular filtration rate, GFR). AKI, które zastąpiło w ostatnich latach termin ostra niewydolność nerek, jest rozpoznawane między innymi u pacjentów po operacjach kardiochirurgicznych, w wyniku nefrotoksycznego uszkodzenia radiokontrastem podczas zabiegów naczyniowych i badań obrazowych, u pacjentów oddziałów intensywnej terapii, we wstrząsie septycznym. Stężenie surowiczej kreatyniny jest ciągle głównym testem diagnostycznym, chociaż zmienia się w przebiegu AKI później niż GFR, który stanowi dokładniejszy wskaźnik czynności nerek. Użyteczność stężenia kreatyniny jako obiektywnego parametru jest jednak ograniczona, ponieważ zależy ono od wielu czynników, w tym od stopnia nawodnienia, diety, masy ciała, masy mięśniowej, wieku, płci, stosowanych leków. Nowe badania zaprezentowały inne, bardziej użyteczne laboratoryjne markery AKI, możliwe do oznaczenia w surowicy i/lub w moczu. Należą do nich m.in. cystatyna C, NGAL, KIM-1, L-FABP i IL-18. Nowe biomarkery stwarzają większe możliwości we wczesnym wykrywaniu AKI, a także mogą określać stopień uszkodzenia nerek w przebiegu AKI. Mogą być również przydatne w prognozowaniu zagrożenia przewlekłą chorobą nerek (PChN) w wyniku AKI lub z innych przyczyn. Celem opracowania jest przedstawienie przeglądu aktualnych doniesień dotyczących zastosowania nowych biomarkerów we wczesnym wykrywaniu AKI oraz progresji do PChN.
Discipline
Year
Volume
7
Issue
4
Pages
319-325
Physical description
References
  • 1. Ostermann M., Chang R.W: Acute kidney injury in the intensive care unit according to RIFLE. Crit. Care Med. 2007; 35: 1837-1843.
  • 2. Zdrojewski Z.: Zapobieganie ostremu uszkodzeniu nerek. Forum Nefrologiczne 2010; 3: 243-251.
  • 3. Uchino S., Kellum JA, Bellomo R. i wsp.; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-818.
  • 4. Park M., Coca S.G., Nigwekar S.U. i wsp.: Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review. Am. J. Nephrol. 2010; 31: 408-418.
  • 5. Coca S.G.: Long-term outcomes of acute kidney injury. Curr. Opin. Nephrol. Hypertens. 2010; 19: 266-272.
  • 6. Lisowska-Myjak B.: Laboratoryjne wskaźniki ostrego uszkodzenia nerek oznaczane w moczu i w surowicy. Forum Nefrologiczne 2010; 3: 71-81.
  • 7. Trachtman H., Christen E., Cnaan A. i wsp.; Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial: Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr. Nephrol. 2006; 21: 989-994.
  • 8. Goldstein S.L., Devarajan P: Progression from acute kidney injury to chronic kidney disease: a pediatric perspective. Adv. Chronic Kidney Dis. 2008; 15: 278-283.
  • 9. Ding H., He Y., Li K. i wsp.: Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin. Immunol. 2007; 123: 227-234.
  • 10. Piwowar A., Warwas M.: Cystatyna C jako wskaźnik przesączania klębuszkowego nerek. Postępy Hig. Med. Dośw. 2001; 55: 687-695.
  • 11. Grubb A.O.: Cystatin C - properties and use as diagnostic marker. Adv. Clin. Chem. 2000; 35: 63-99.
  • 12. Andersen TB., Eskild-Jensen A., Fr0kiaer J., Br0chner-Mortensen J.: Measuring glomerular filtration rate in children; can cystatin C replace established methods? A review. Pediatr. Nephrol. 2009; 24: 929-941.
  • 13. Chertow G.M., Burdick E., Honour M. i wsp.: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 2005; 16: 3365-3370.
  • 14. Filler G., Bokenkamp A., Hofmann W i wsp.: Cystatin C as a marker of GFR - history, indications, and future research. Clin. Biochem. 2005; 38: 1-8.
  • 15. Bardi E., Bobok I., Olah A.V i wsp.: Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatr. Nephrol. 2004; 19: 1145-1147.
  • 16. Marchewka Z.: Low molecular weight biomarkers in the nephrotoxicity. Advances in Clinical and Experimental Medicine 2006; 15: 1129-1138.
  • 17. Małyszko J.: Zespół sercowo-nerkowy. Forum Nefrologiczne 2011; 4: 81-90.
  • 18. Mishra J., Mori K., Ma Q. i wsp.: Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cis-platin nephrotoxicity. Am. J. Nephrol. 2004; 24: 307-315.
  • 19. Mishra J., Ma Q., Prada A. i wsp.: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003; 14: 2534-2543.
  • 20. Hemdahl A.L., Gabrielsen A., Zhu C. i wsp.: Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 136-142.
  • 21. Wagener G., Jan M., Kim M. i wsp.: Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006; 105: 485-491.
  • 22. Wheeler D.S., Devarajan P., Ma Q. i wsp.: Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit. Care Med. 2008; 36: 1297-1303.
  • 23. Mussap M., Degrandi R., Fravega M., Fanos V: Acute kidney injury in critically ill infants: the role of urine Neutrophil Gelatinase-Associated Lipocalin (NGAL). J. Matern. Fetal Neonatal Med. 2010; 23 supl. 3: 70-72.
  • 24. Du Y., Zappitelli M., Mian A. i wsp.: Urinary biomarkers to detect acute kidney injury in the pediatric emergency center. Pediatr. Nephrol. 2011; 26: 267-274.
  • 25. Nguyen M.T., Devarajan P.: Biomarkers for the early detection of acute kidney injury. Pediatr. Nephrol. 2008; 23: 2151-2157.
  • 26. Wagener G., Gubitosa G., Wang S. i wsp.: Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am. J. Kidney Dis. 2008; 52: 425-433.
  • 27. Bennett M., Dent C.L., Ma Q. i wsp.: Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin. J. Am. Soc. Nephrol. 2008; 3: 665-673.
  • 28. Mishra J., Dent C., Tarabishi R. i wsp.: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
  • 29. Niemczyk S., Giers K.: Nefropatia pokontrastowa. Terapia 2008; 11: 60-64.
  • 30. Kagan A., Sheikh-Hamad D.: Contrast-induced kidney injury: focus on modifiable risk factors and prophylactic strategies. Clin. Cardiol. 2010; 33: 62-66.
  • 31. Jobs K, Rączka A., Jung A., Lichosik M.: Ocena stężenia ludzkiej obojętnochłonnej lipokaliny (NGAL) w surowicy i moczu dzieci z wadami układu moczowego, poddanych badaniu z użyciem dożylnego środka kontrastowego - doniesienie wstępne. Pediatr. Med. Rodz. 2010; 6: 44-47.
  • 32. Haase M., Bellomo R., Devarajan P. i wsp.; NGAL Metaanalysis Investigator Group: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 2009; 54: 1012-1024.
  • 33. Wasilewska A., Zoch-Zwierz W, Taranta-Janusz K., Michaluk-Skutnik J.: Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr. Nephrol. 2010; 25: 889-897.
  • 34. Devarajan P: The use of targeted biomarkers for chronic kidney disease. Adv. Chronic Kidney Dis. 2010; 17: 469-479.
  • 35. Mitsnefes M.M., Kathman T.S., Mishra J. i wsp.: Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr. Nephrol. 2007; 22: 101-108.
  • 36. Bolignano D., Lacquaniti A., Coppolino G. i wsp.: Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press. Res. 2008; 31: 255-258.
  • 37. Al-Ismaili Z., Palijan A., Zappitelli M.: Biomarkers of acute kidney injury in children: discovery, evaluation, and clinical application. Pediatr. Nephrol. 2011; 26: 29-40.
  • 38. Goldstein S.L., Devarajan P.: Acute kidney injury in childhood: should we be worried about progression to CKD? Pediatr. Nephrol. 2011; 26: 509-522.
  • 39. Bolignano D., Coppolino G., Campo S. i wsp.: Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am. J. Nephrol. 2007; 27: 373-378.
  • 40. Meijer E., Boertien WE., Nauta F.L. i wsp.: Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a crosssectional analysis. Am. J. Kidney Dis. 2010; 56: 883-895.
  • 41. Brunner H.I., Mueller M., Rutherford C. i wsp.: Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2006; 54: 2577-2584.
  • 42. Suzuki M., Wiers K.M., Klein-Gitelman M.S. i wsp.: Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr. Nephrol. 2008; 23: 403-412.
  • 43. Bolignano D., Coppolino G., Campo S. i wsp.: Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol. Dial. Transplant. 2008; 23: 414-416.
  • 44. Bolignano D., Lacquaniti A., Coppolino G. i wsp.: Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4: 337-344.
  • 45. Yang Y.H., He X.J., Chen S.R. i wsp.: Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 2009; 36: 45-51.
  • 46. van Timmeren M.M., van den Heuvel M.C., Bailly V i wsp.: Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J. Pathol. 2007; 212: 209-217.
  • 47. Liangos O., Tighiouart H., Perianayagam M.C. i wsp.: Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14: 423-431.
  • 48. Zhang J., Goering P.L., Espandiari P. i wsp.: Differences in immunolocalization of KIM-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine. Toxicol. Pathol. 2009; 37: 629-643.
  • 49. Wasilewska A., Taranta-Janusz K., Dębek W i wsp.: KIM-1 and NGAL: new markers of obstructive nephropathy. Pediatr. Nephrol. 2011; 26: 579-586.
  • 50. Edelstein C.L., Hoke T.S., Somerset H. i wsp.: Proximal tubules from caspase-1-deficient mice are protected against hypoxia-induced membrane injury. Nephrol. Dial. Transplant. 2007; 22: 1052-1061.
  • 51. Washburn K.K., Zappitelli M., Arikan A.A. i wsp.: Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol. Dial. Transplant. 2008; 23: 566-572.
  • 52. Ariarajah N., Gerstel E., Martin P.Y., Ponte B.: Biomarkers in acute kidney injury: an update. Rev. Med. Suisse 2011; 7: 490-494.
  • 53. Parikh C.R., Mishra J., Thiessen-Philbrook H. i wsp.: Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006; 70: 199-203.
  • 54. Kamijo-Ikemori A., Sugaya T., Obama A. i wsp.: Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am. J. Pathol. 2006; 169: 1107-1117.
  • 55. Ferguson MA., Vaidya VS., Waikar S.S. i wsp.: Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int. 2010; 77: 708-714.
  • 56. Portilla D., Dent C., Sugaya T. i wsp.: Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008; 73: 465-472.
  • 57. Doi K., Noiri E., Maeda-Mamiya R. i wsp.: Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit. Care Med. 2010; 38: 2037-2042.
  • 58. Nakamura T., Sugaya T, Node K. i wsp.: Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am. J. Kidney Dis. 2006; 47: 439-444.
  • 59. Kamijo A., Sugaya T., Hikawa A. i wsp.: Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol. Cell. Biochem. 2006; 284: 175-182.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-62190977-2b81-4d22-beb0-8803d629ce10
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.